p. −
2345-3729
Vol.6/No.1(winter)
p. 13−18
2345-3729
Vol.6/No.1(winter)
p. 19−22
2345-3729
Vol.6/No.1(winter)
p. 23−28
2345-3729
Vol.6/No.1(winter)
p. 29−35
2345-3729
Vol.6/No.1(winter)
18 yrs. and performance status (PS) of 0-2 (ECOG). All patients were given paclitaxel (200 mg/m2 ) and carboplatin (AUC 6) on day 1, every 21 days and celecoxib (400 mg) daily. Results: Most of the patients were male and the mean age was 58 yrs. Old. Performance status 0, 1, and 2 were 8.2%, 40.5% and 51.3%, respectively. Four patients were in stage IIIA (10.8%), 12 patients in stage IIIB (32.4%) and 21 (56.8%) in stage IV. The overall response rate was 54%. Time to progression and median overall survival were 5.7 and 9 months, respectively. Only one patient had grade 3 anemia. There was no grade 4 cytotoxicity. Three patients had cytotoxic drug allergy. Conclusion: Based on this study, adding 400 mg celecoxib to the standard regimen (paclitaxel plus carboplatin) does not enhance time to progression and overall survival compared to historical data. Thus, we recommend combining higher dosage of celecoxib with other targeted agents in phase I/II trials. (Tanaffos 2007; 6(1): 37-46)]]>
p. 37−46
2345-3729
Vol.6/No.1(winter)
p. 47−51
2345-3729
Vol.6/No.1(winter)
0.05), 5.4% had a history of absence from class because of wheezing or dyspnea. Conclusion: We found a relatively high prevalence of wheezing among young adult university students. Our findings suggest that cigarette smoking is common among young university students with asthma symptoms. Adequate public health measures are needed to prevent smoking among Iranian young adults, and medical students should be better educated with regard to asthma and the risks of smoking. (Tanaffos 2007; 6(1): 53-58)]]>
p. 53−58
2345-3729
Vol.6/No.1(winter)
p. 59−65
2345-3729
Vol.6/No.1(winter)
p. 67−70
2345-3729
Vol.6/No.1(winter)
p. 71−74
2345-3729
Vol.6/No.1(winter)
p. 75−79
2345-3729
Vol.6/No.1(winter)
p. 81−83
2345-3729
Vol.6/No.1(winter)